Advertisement
Advertisement
Skip to content
Follow Us on
Advertisement
TOP STORIES
Business

Glenmark Pharmaceuticals launches generic version of INLYTA in the US market

Advertisement

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of its authorized generic version of INLYTA® (axitinib) tablets in the United States. The newly launched Axitinib Tablets are available in 1 mg and 5 mg dosages. This development signifies Glenmark’s ongoing efforts to provide affordable medication options to patients in the US market.

The original INLYTA® tablets, a registered trademark of Pfizer Inc., are used primarily in the treatment of advanced renal cell carcinoma. According to IQVIA® sales data, the annual sales of INLYTA® tablets in the United States reached approximately $538.4 million for the 12-month period ending September 2026. The introduction of Glenmark’s generic version is expected to offer a cost-effective alternative to patients and healthcare providers, potentially impacting the market dynamics for this category of oncology medication.

Marc Kikuchi, President and Business Head for North America at Glenmark, emphasized the company’s commitment to enhancing access to quality healthcare. “The launch of Axitinib Tablets reinforces Glenmark’s commitment to expanding access to quality, affordable medicines for patients in the United States,” Kikuchi stated. He further highlighted the strategic importance of this product addition in addressing the evolving needs of patients and healthcare providers.

Glenmark Pharmaceuticals Limited is a global pharmaceutical company known for its focus on innovation and accessibility. With a presence in over 80 countries, the company operates 11 manufacturing facilities and six R&D centres worldwide. Its diversified portfolio spans branded, innovative, generics, and consumer health products, with a particular focus on respiratory, dermatology, and oncology sectors.

The launch of Glenmark’s authorized generic version of INLYTA® tablets is anticipated to influence the competitive landscape of the oncology drug market in the US. Analysts and market observers will likely monitor the impact of this launch on Glenmark’s market share and the broader implications for pricing and accessibility in the oncology segment.

Advertisement

Join TaxGuru's Network for the latest updates on Income Tax, GST, Company Law, Corporate Laws and other related subjects.

Leave a Reply

Your email address will not be published. Required fields are marked *